Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study"

NCT00344149 is registered in ClinicalTrials.gov with Ostfold Hospital Trust as lead sponsor.

NCT NCT00344149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00344149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study"
Lead sponsor
Ostfold Hospital Trust
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
March 31, 2014
Enrollment
112 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia (itp)